Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney

References 

1. US Renal Data Systems, USRDS 2007, Annual Data Report, NIH, NIDDK Bethesda MD, Accessed via www.usrds.com (March 4th 2007).
2. Chaturvedi N, Sjoelie AK, Svensson A. The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. JRAAS. 2002;3:255–261
3. The DCCT Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977–986
   • MEDLINE
   • CrossRef
4. UK Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713
   • MEDLINE
   • CrossRef
5. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia. 2001;44:1957–1972
   • MEDLINE
   • CrossRef
6. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am. J. Kid Dis. 2000;36:449–467
7. The EUCLID Study Group . Randomised placebo-control trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787–1792
   • Abstract
   • Full Text
   • Full-Text PDF (78 KB)
   • CrossRef
8. Chaturvedi N, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet. 1998;351:28–31
   • Abstract
   • Full Text
   • Full-Text PDF (77 KB)
   • CrossRef
9. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Ilief IP, Brusegan V, et al Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2004;351:1941–1951
   • CrossRef
10. The DIRECT Programme Study Group . The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. JRAAS. 2005;6:25–32